The latest developments across the fields of stem cell transplantation and cellular therapy were presented at the 2024 Tandem Meetings in San Antonio, Texas, from February 21-24, 2024.
The 2024 Transplantation and Cellular Therapy Tandem Meetings took place in San Antonio, Texas from February 21 to 24, 2024, where experts in the field of hematologic oncology met to learn and share results of the latest research.
While the latest findings in stem cell transplantation often take center stage, some of the most compelling data came from studies on chimeric antigen receptor (CAR) T-cell therapies. These studies included the CARTITUDE-2 study (NCT04133636) of ciltacabtagene autoleucel (cilta-cel; Carvykti) in relapsed or refractory multiple myeloma and the TRANSCEND CLL 004 (NCT03331198) and TRANSCEND NHL 001 (NCT02631044) trials of lisocabtagene maraleucel (liso-cel; Breyanzi).
Developments in the graft-vs-host disease (GVHD) space also were among some of the most anticipated at the meetings. These included promising data from a retrospective analysis showing that Orca-T may have an advantage over posttransplant cyclophosphamide regarding survival in GVHD.
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More
UGN-101 Shows Promise for Upper Tract Urothelial Cancer Durability
May 5th 2024Maintenance UGN-101 therapy demonstrated good durability of response in initial responders with low-grade upper tract urothelial cancer, as evidenced by a low rate of disease progression in a multicenter, longitudinal follow-up study.
Read More
Nivolumab With Gemcitabine-Cisplatin Boosts Survival in Metastatic Urothelial Carcinoma
May 5th 2024Combination therapy with nivolumab and gemcitabine-cisplatin showed promising results in treating metastatic urothelial carcinoma with significantly improved overall survival and progression-free survival rates.
Read More